About
Johnny Page is a biotech entrepreneur and co-founder/CEO of Bolden Therapeutics, a company developing neurogenesis-promoting therapies for central nervous system diseases. Bolden says he earned an A.B. in Music, Sc.B. in Neuroscience, and Sc.M. in Biotechnology from Brown University, completed two years at Alpert Medical School, and also completed MIT I-Corps Spark entrepreneurship training. He appears to be an operating founder in neuroscience/biotech rather than an investor or fund manager.
Areas of interest
biotechnologyneuroscienceneurogenesisCNS therapeuticsneurodegenerative diseaseAlzheimer's diseaseantisense oligonucleotidesdrug development